Levocetirizina

Levocetirizine, the active ingredient in Levocetirizina, is an antihistamine presented as an oral dosage form for oral use. It reduces symptoms of allergic rhinitis and chronic urticaria by blocking peripheral H1 receptors, and is prescribed for adults and children under medical supervision.

GNH USA supplies Levocetirizina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Customers benefit from reliable supply chains, comprehensive documentation, and responsive technical support throughout the procurement process.

Levocetirizine is used to manage allergic conditions by antagonising peripheral H1 receptors.

Allergic rhinitis: alleviates sneezing, nasal congestion, itching and rhinorrhoea associated with seasonal or perennial triggers. Chronic urticaria: reduces the frequency and intensity of hives and associated itching. Seasonal allergic rhinitis: provides symptom control during pollen‑driven allergy periods.

Levocetirizine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Drowsiness or mild sedation. - Dry mouth. - Headache. - Fatigue. - Nausea. - Dizziness.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis). - Thrombocytopenia. - Hepatic enzyme elevation. - Cardiac arrhythmia (rare). - Angio‑edema. - Persistent or worsening rash.

Before initiating therapy, consider the following safety measures.

Pregnancy: consult a healthcare professional; safety data are limited. Breastfeeding: assess risk versus benefit with a clinician. Renal impairment: dose adjustment may be required under medical guidance. Elderly patients: monitor for increased sedation. Concomitant CNS depressants: avoid excessive drowsiness. Store at ambient temperature: keep below 25 °C, retain in original packaging and protect from moisture.

Levocetirizine may interact with other medicines; monitor accordingly.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole) – may increase plasma levels. - Alcohol or other sedatives – can potentiate drowsiness.

Moderate Interactions (Monitor Closely): - Anticholinergic agents – may exacerbate dry mouth. - Theophylline – possible additive CNS effects. - Rifampicin – may reduce levocetirizine exposure. - Certain antihypertensives – monitor blood pressure changes.